SOLIAN TABLET 200mg

Product Information

Registration Status: Active

SOLIAN TABLET 200mg is approved to be sold in Singapore with effective from 1998-05-16. It is marketed by SANOFI-AVENTIS SINGAPORE PTE LTD, with the registration number of SIN09773P.

This product contains Amisulpride 200mg in the form of TABLET. It is approved for ORAL use.

This product is manufactured by Sanofi Winthrop Industrie in FRANCE.

It is a Prescription Only Medicine that can only be obtained from a doctor or a dentist, or a pharmacist with a prescription from a Singapore-registered doctor or dentist.

Amisulpride

Description

Amisulpride (trade name Solian) is an antipsychotic drug sold by Sanofi-Aventis. It is not approved for use in the United States, but is approved for use in Europe and Australia for the treatment of psychoses and schizophrenia. Additionally, it is approved in Italy for the treatment of dysthymia (under the brand name Deniban). Amisulpride is a selective dopamine antagonist.

Indication

Investigated for use/treatment in schizophrenia and schizoaffective disorders, mania in bipolar disorder, and depression.

Mechanism of Action

Amisulpride binds selectively to dopamine D(2) and D(3) receptors in the limbic system. Low doses of amisulpride preferentially block presynaptic D(2)/D(3)-dopamine autoreceptors, thereby enhancing dopaminergic transmission, whereas higher doses block postsynaptic receptors, thus inhibiting dopaminergic hyperactivity. It may also have 5-ht7 antagonistic effect, useful in depression treatment.

Pharmacokinetics

Absorption
Bioavailability is 48% following oral administration.
Distribution
Metabolism
Elimination

Toxicity

Overdoses of amisulpride have been linked with torsades de pointes.

Active Ingredient/Synonyms

4-Amino-N-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-2-methoxybenzamide | 4-Amino-N-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-O-anisamide | Aminosultopride | Amisulprida | Amisulpridum | Amisulpride |


Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.

References

  1. Health Science Authority of Singapore - Reclassified POM
  2. Drugbank